成都康弘药业集团股份有限公司 CHENGDU KANGHONG PHARMACEUTICALS GROUP CO.LTD
{{company.company_channel.channel_name}}
{{company.company_name_local}}
{{company.company_channel.channel_name}}
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept 2021-02-03 22:00
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial 2020-12-23 22:40
1